Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, the 2.4mg semaglutide dose—the highest maintenance dose—typically produces greater weight loss than lower doses in clinical trials. The STEP trials showed patients on 2.4mg lost approximately 15% of body weight over 68 weeks, compared to placebo. However, individual results vary significantly based on metabolic factors, genetics, and how the body processes GLP-1 receptor signaling.

For people considering semaglutide therapy, understanding what drives individual response is critical. PlexusDx focuses on precision wellness by integrating biomarker assessment and genetic predispositions into the treatment conversation, helping patients and providers move beyond assuming everyone responds identically to the highest available dose.

Semaglutide Dose-Response Evidence: What Clinical Trials Actually Show

The STEP 1–5 trials established a clear dose-response relationship with semaglutide. Patients escalated from 0.25mg weekly to 2.4mg over 16 weeks experienced progressive weight loss increases. At the 2.4mg maintenance dose, average weight loss was 15.3% of baseline body weight after 68 weeks, substantially more than the 2.4% seen with placebo.

Notably, not all participants achieved maximum weight loss at the highest dose. Some responded robustly at 1.7mg; others required 2.4mg for meaningful results. A minority experienced diminishing returns or side effects that required dose adjustment downward. This variability underscores why a one-size-fits-all approach may miss optimal outcomes for individual patients.

Genetic and Metabolic Factors That Influence Individual Semaglutide Response

Response to semaglutide is not solely determined by dose. Genetic variants in GLP-1 receptor pathways, appetite-regulation genes, and metabolic pathways influence how the body responds to therapy. Common variants in genes like GLP1R, GIPR, FTO, and MC4R may affect satiety signaling, baseline weight, and the magnitude of weight loss achieved.

Genetic Factor Relevance to Semaglutide Response
GLP1R rs6923761 Influences GLP-1 receptor function and appetite suppression magnitude
GIPR rs1800437 Affects glucose-dependent insulinotropic peptide pathway; may influence metabolic response
FTO rs9939609 Associated with baseline obesity risk and appetite regulation; may modulate treatment responsiveness
MC4R rs17782313 Impacts melanocortin-4 receptor signaling; relates to appetite and weight regulation

Biomarker-Informed Dosing: Moving Beyond Assumption-Based Escalation

Traditional semaglutide protocols escalate all patients to the highest tolerated dose. However, biomarker assessment—including fasting glucose, insulin levels, HbA1c, lipid panel, inflammatory markers, and genetic predispositions—can provide context for personalizing the approach. Patients with specific metabolic profiles may achieve optimal outcomes at lower doses with better tolerability.

A provider considering semaglutide can use biomarker data to predict which patients may be sensitive to GLP-1 signaling, predisposed to side effects, or likely to respond robustly at moderate doses. This precision-informed strategy may reduce unnecessary escalation and support more sustainable, patient-centered treatment plans aligned with individual physiology.

Safety, Tolerability, and Identifying Who Benefits Most from Dose Escalation

Higher semaglutide doses increase the risk of gastrointestinal side effects—nausea, vomiting, constipation, and diarrhea. For some patients, these effects resolve with time; for others, they persist or necessitate dose reduction. Individuals with a history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should not use semaglutide. Pregnant or breastfeeding patients and those with severe renal or hepatic disease require careful provider assessment.

Before escalating to 2.4mg, a qualified provider should evaluate baseline tolerability, gastrointestinal history, and clinical markers. Patients experiencing meaningful weight loss and improved metabolic health at 1.7mg may not benefit from escalation; those with suboptimal response and good tolerability may warrant continuation to 2.4mg. Individual medical history, not dose alone, should guide this decision.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for how an individual's GLP-1 and GIPR receptor pathways, appetite-regulation genes, and metabolic predispositions align with semaglutide therapy. This information should be interpreted with a qualified healthcare provider to inform informed, personalized treatment conversations rather than assuming all patients respond identically to the 2.4mg dose.

The genetic test reveals predispositions in peptide genetic pathways—including GLP1R, GIPR, FTO, and MC4R variants—that relate to appetite signaling and metabolic response. This is not a pharmacogenetic prediction of exact medication response; rather, it contextualizes the individual's genetic backdrop for how they may experience appetite suppression, satiety, and weight-loss capacity on GLP-1 therapy.

When combined with clinical biomarkers and medical history, genetic insights can support a more informed conversation between patient and provider about optimal dosing strategy, expected outcomes, and personalized protocol design—whether that involves starting with compounded semaglutide at a conservative dose or escalating based on tolerability and response.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves